Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
CA 2291740 C · Owner: Claragen, Inc. · Inventors: Pilon, Aprile L.; Zhang, Zhongjian; Mukherjee, Anil B.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods for treatment of inflammatory and fibrotic conditions in vivo using UG is disclosed. Methods for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG are also disclosed. Compositions containing UG, optionally containing lung surfactant and assay procedures for detection of UG-fibronectin complexes are also , provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 28, 1998 and granted July 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 28, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 28, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.